Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
RuBi-Glutamate is a ruthenium-bipyridine-trimethylphosphine caged glutamate that can be excited by visible wavelengths and releases glutamate after one- or two-photon excitation. Has high quantum efficiency and can be used at low concentrations, partly avoiding blockade of GABAergic transmission seen with other caged glutamate compounds. Displays high spatial resolution and generates excitatory responses in individual dendritic spines with physiological kinetics.
MNI-caged-L-glutamate (Cat. No. 1490) also available.
Sold under licence from Columbia University
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 970.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||5.15 mL||25.76 mL||51.52 mL|
|1 mM||1.03 mL||5.15 mL||10.3 mL|
|2 mM||0.52 mL||2.58 mL||5.15 mL|
|10 mM||0.1 mL||0.52 mL||1.03 mL|
References are publications that support the biological activity of the product.
Fino et al (2009) RuBi-Glutamate: two-photon and visible-light photoactivation of neurons and dendritic spines. Front.Neural Circuits 3 1 PMID: 19506708
Salierno et al (2010) A fast ruthenium polypyridine cage complex photoreleases glutamate with visible or IR light in one and two photon regimes. J.Inorg.Biochem. 104 418 PMID: 20060592
If you know of a relevant reference for RuBi-Glutamate, please let us know.
Keywords: RuBi-Glutamate, RuBi-Glutamate supplier, Caged, Glutamate, mGluR, iGluR, Receptors, agonists, ionotropic, metabotropic, Miscellaneous, Compounds, 3574, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for RuBi-Glutamate include:
Tazerart et al (2020) Spike-timing-dependent plasticity rule for single, clustered and distributed dendritic spines. Nat Commun 11 4276 PMID: 32848151
Mitchell et al (2019) Probing Single Synapses via the Photolytic Release of Neurotransmitters Front Synaptic Neurosci 11 PMID: 31354469
Kazemipour et al (2019) Kilohertz frame-rate two-photon tomography. Nat Methods 16 778 PMID: 31363222
Blaesse et al (2015) μ-Opioid Receptor-Mediated Inhibition of Intercalated Neurons and Effect on Synaptic Transmission to the Central Amygdala. Neuroscience 35 7317 PMID: 25972162
Paz et al (2018) Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac. Neuropharmacology 137 309 PMID: 29758221
Do you know of a great paper that uses RuBi-Glutamate from Tocris? Please let us know.
Average Rating: 5 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Recording from a DA neuron in the periaqueductal gray. A 6 x 6 grid was used to locally uncage Rubi-glutamate (300 micromolar) in an area surrounding the neuron. Representative trace showing the responses to each focal stimulation in current-clamp mode.
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.